Evidence map›Paper›PMID 42452583›Full record

ReviewJournal of clinical medicine2026

Emerging Serological Biomarkers for Autoimmune Hepatitis.

Kazumichi Abe, Jun Wada, Hiromasa Ohira

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Kazumichi AbeDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima City 960-1295, Japan.ORCID 0000-0001-5359-9465
Jun WadaDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima City 960-1295, Japan.
Hiromasa OhiraDepartment of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima City 960-1295, Japan.

Funding

Japan Society for the Promotion of Science 23K07379
6 · The paper itself

Abstract

Autoimmune hepatitis (AIH) lacks a disease-specific diagnostic biomarker, particularly for patients who present with acute onset, normal IgG levels, or seronegative profiles. Recent advances in high-throughput autoantibody profiling technologies have enabled the systematic discovery of novel AIH-associated autoantigens. This review summarizes emerging autoantibodies that have been identified through proteome-wide screening approaches, including human protein microarrays and phage immunoprecipitation sequencing. Particular attention is given to anti-docking protein 2 (DOK2) and anti-mitochondrial ribosomal protein S27 (MRPS27) antibodies, which have shown promising diagnostic performance. Importantly, the combined assessment of these autoantibodies markedly improves the diagnostic sensitivity for AIH and may be useful for screening or clinical triage, although its reduced specificity limits its use as a stand-alone confirmatory test. We also discuss how the integration of serological biomarkers with molecular pathology and spatial immune analysis may advance the understanding of AIH pathogenesis. These developments highlight the potential of proteome-wide autoantibody discovery to refine diagnostic strategies for AIH and provide new insights into disease mechanisms.

Indexed as

autoantibodyautoimmune hepatitisdocking protein 2human protein microarraymitochondrial ribosomal protein S27

Identifiers

PMID42452583
PMCPMC13362522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.